The global cancer immunotherapy market is accounted for $45,471 million in 2015, and is estimated to reach $117,114 million by 2022, growing at a CAGR of 14.5% during the analysis period of 2016-2022. Cancer Immunotherapy is a method of cancer treatment that boosts the immune system in fighting cancer. This therapy is more advantageous than the traditional approach as it delivers long-term protection against cancer, has minimal side effects, and avails treatment to more cancer types. Immunotherapy works by guiding system toward cancer-specific targets, followed by activation of immune system to mobilize the target, and produces response that can eradicate cancer targeted cells. There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global cancer immunotherapy market. However, the factors such as lack of awareness about cancer immunotherapy are anticipated to inhibit the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.
The market is segmented based on technology, application, end-users, and geography. By technology, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other technologies. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By end-users, it is divided into hospitals, cancer research centers, and clinics. Geographically, it is studied across North America, Europe, Asia Pacific, and LAMEA.
KEY MARKET BENEFITS:
KEY MARKET SEGMENT:
List of players profiled in the report
List of other players (These companies are not profiled in the report and same can be done on demand)
Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep ...
November 2017 | $5370 |View Details>>
The Global Drugs for Malaria market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Drugs for Malaria market, especially in North America, Europe, Asia-Pacific, South ...
November 2017 | $4960 |View Details>>
In 2016, the Asia-Pacific Drugs for Malaria market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Drugs for Malaria in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and ...
November 2017 | $4660 |View Details>>
In 2016, the Drugs for Malaria market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include Cipla Guilin Pharmaceutical ...
November 2017 | $3360 |View Details>>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research